Nascent Biotech (NBIO) 10-K 29 Jun 23 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Mar. 31, 2023	Jun. 29, 2023	Sep. 30, 2022
Cover [Abstract]
Entity Registrant Name	NASCENT BIOTECH INC.
Entity Central Index Key	0001622057
Document Type	10-K
Amendment Flag	false
Entity Voluntary Filers	No
Current Fiscal Year End Date	--03-31
Entity Well Known Seasoned Issuer	No
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Mar. 31, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Entity Common Stock Shares Outstanding		141,401,528
Entity Public Float			$ 19,168,087
Document Annual Report	true
Document Transition Report	false
Entity File Number	000-55299
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	46-5001940
Entity Interactive Data Current	Yes
Entity Address Address Line 1	631 US Hwy 1 Suite 407
Entity Address State Or Province	FL
Entity Address Postal Zip Code	33408
City Area Code	612
Local Phone Number	961-5656
Entity Address City Or Town	N Palm Beach
Auditor Firm Id	5525
Auditor Location	Spokane, Washington
Auditor Name	Fruci & Associates II, PLLC

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Current assets:
Cash	$ 172,186	$ 94,414
Prepaid	82,816	11,000
Total current assets	255,002	105,414
Total assets	255,002	105,414
Current liabilities:
Accounts payable and accrued expense	498,122	776,890
Convertible note- net of discount	389,591	0
Derivative liability	663,426	0
Total current liabilities	1,551,139	776,890
Total liabilities	1,551,139	776,890
Commitments and Contingencies	0	0
Stockholders' equity:
Preferred stock, $0.001 par value,50,000,000 authorized, zero Series A issued and outstanding, respectively	0	0
Common stock, $0.001 par value, 500,000,000 authorized, 131,764,348 and 111,313,175 issued and outstanding, respectively	131,764	111,313
Additional paid-in capital	20,194,874	18,039,017
Accumulated deficit	(21,622,775)	(18,821,806)
Total stockholders' equity (deficit)	(1,296,137)	(671,476)
Total liabilities and stockholders' equity	$ 255,002	$ 105,414

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2023	Mar. 31, 2022
Stockholders deficit
Preferred stock shares par value	$ 0.001	$ 0.001
Preferred stock shares authorized	50,000,000	50,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock shares par value	$ 0.001	$ 0.001
Common stock shares authorized	500,000,000	500,000,000
Common stock shares issued	131,764,348	111,313,175
Common stock shares outstanding	131,764,348	111,313,175

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenue	$ 0	$ 1,000,000
Operating expenses:
Consulting expense	1,096,245	547,933
General and administrative expense	389,767	379,424
Clinical trials	383,688	332,289
Research and development	270,529	197,406
Total operating expense	2,155,757	1,457,052
Income (loss) from operations	(2,155,757)	(457,052)
Other income (expense):
Interest income	274	12
Interest expense	(1,566,919)	(48,004)
Finance costs	(5,124)	(151,150)
Gain on debt forgiveness	28,000	5,000
Original interest debt discount	(156,229)	(287,979)
Gain on change in fair value of derivative liabilities	1,054,786	468,823
Total other income (expense)	(645,212)	(13,338)
Net income (loss) before income tax	(2,800,969)	(470,390)
Income tax	0	0
Net income (loss)	$ (2,800,969)	$ (470,390)
Net income (loss) per share, basic and diluted	$ (0.02)	$ 0
Weighted average number of shares outstanding, basic and diluted	118,569,028	107,741,761

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT) - USD ($)	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance, shares at Mar. 31, 2021		54,130	104,834,083
Balance, amount at Mar. 31, 2021	$ (472,505)	$ 54	$ 104,834	$ 17,774,023	$ (18,351,416)
Common stock for service, shares			50,000
Common stock for service, amount	5,250	0	$ 50	5,200	0
Common stock to related parties for service, shares			1,513,719
Common stock to related parties for service, amount	110,836	0	$ 1,514	109,322	0
Common stock to related parties for conversion of payables, shares			2,407,010
Common stock to related parties for conversion of payables, amount	128,333	0	$ 2,407	125,926	0
Common stock for conversion of payables, shares			540,000
Common stock for conversion of payables, amount	27,000	$ 0	$ 540	26,460	0
Common stock issued for the conversion of preferred shares, shares		(54,130)	1,968,363
Common stock issued for the conversion of preferred shares, amount	0	$ (54)	$ 1,968	(1,914)	0
Net loss	(470,390)	0	$ 0	0	(470,390)
Balance, shares at Mar. 31, 2022			111,313,175
Balance, amount at Mar. 31, 2022	(671,476)	0	$ 111,313	18,039,017	(18,821,806)
Net loss	(2,800,969)	0	$ 0	0	(2,800,969)
Common stock issued for services, shares			1,000,000
Common stock issued for services, amount	60,000	0	$ 1,000	59,000	0
Common stock issued for conversion of payables , shares			37,700
Common stock issued for conversion of payables , amount	9,275	0	$ 38	9,237	0
Common stock issued to related party for service, shares			3,815,414
Common stock issued to related party for service, amount	624,320	0	$ 3,815	620,505	0
Common stock issued for the conversion of debt, shares			11,398,059
Common stock issued for the conversion of debt, amount	1,023,974	0	$ 11,398	1,012,576	0
Common stock issued for the conversion of warrants, shares			4,200,000
Common stock issued for the conversion of warrants, amount	208,000	0	$ 4,200	203,800
Warrants issued with convertible notes	178,739	0	0	178,739	0
Stock option expense	72,000	0	$ 0	72,000	0
Balance, shares at Mar. 31, 2023			131,764,348
Balance, amount at Mar. 31, 2023	$ (1,296,137)	$ 0	$ 131,764	$ 20,194,874	$ (21,622,775)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (2,800,969)	$ (470,390)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	60,000	5,250
Stock based compensation- related parties	624,320	110,835
(Gain) loss on fair value of derivative liabilities	(1,054,786)	(468,823)
Debt discount amortization	1,343,277	325,431
Loss on convertible notes	286,265	0
Stock option expense	72,000	0
Changes in operating assets and liabilities:
Accounts receivable	0	750,000
Prepaid	(71,816)	(11,000)
Accounts payable and accrued expenses	(245,519)	167,060
Due to related parties	0	5,116
Net provided by (cash used) in operating activities	(1,787,228)	413,479
Cash flows from financing activities:
Proceeds from convertible note	1,932,000	200,000
Common stock issued for the exercise of warrants	208,000	0
Repayment of convertible notes	(275,000)	(520,000)
Net cash provided by ( used in) financing activities	1,865,000	(320,500)
Net increase (decrease) in cash	77,772	92,979
Cash - beginning of year	94,414	1,435
Cash - end of year	172,186	94,414
SUPPLEMENT DISCLOSURES:
Interest paid	11,135	30,027
Income taxes paid	0	0
NON MONETARY TRANSACTIONS
Common stock issued for payables - related parties	0	$ 128,333
Common stock issued for retiring preferred shares		1,968
Common stock issued for convertible debt	1,023,974	$ 0
Common stock issued for accounts payable	9,275	27,000
Initial discount from derivatives	$ 178,739	$ 0

ORGANIZATION AND NATURE OF OPER

ORGANIZATION AND NATURE OF OPERATIONS	12 Months Ended
	Mar. 31, 2023
ORGANIZATION AND NATURE OF OPERATIONS
NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS	NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS Nascent Biotech, Inc (“Nascent “the Company”) was incorporated on March 3, 2014 under the laws of the State of Nevada. On July 15, 2014 Biotech entered into a reverse merger with Jin-En Group International Holding Company (Jin-En). Jin-En issued 7,500,200 shares of its common stock for all the outstanding shares of Nascent Biotech, Inc. In addition, Jin-En cancelled 15,000,000 shares of its common stock. Prior to the merger Jin-En had 22,829,400 shares outstanding. Jin-En changed its name to Nascent Biotech, Inc. Jin-En had $19,000 of net liabilities at the date of the merger. The Company is actively developing its primary asset Pritumumab for the treatment of brain cancer and pancreatic cancer. Nascent is also actively researching other cancers that have a high probability of benefiting from the therapeutic effects of Pritumumab because they share a common target. Nascent is a clinical stage biopharmaceutical company that focuses on biologic drug candidates that are preparing for initial clinical testing for the treatment of brain and pancreatic cancer. The Company has completed its phase one trial and submitted the data and protocol to the FDA on March 17, 2023 for review to commence phase 2 clinical trials. Once approval has been received from the FDA, the Company will commence its phase 2 clinical trials.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Mar. 31, 2023
SIGNIFICANT ACCOUNTING POLICIES
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES	NOTE 2- SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. The Company has elected a fiscal year ending on March 31. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Nascent Biotech, Inc. and its wholly-owned subsidiary Nascent Biologics, Inc, which has been inactive since March 2015. All intercompany accounts and transactions have been eliminated. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company as of March 31, 2023 did not have any cash equivalents. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the periods. The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition, and results of operations is highly uncertain and subject to change. We considered the potential impact of the COVID-19 pandemic on our estimates and assumptions and there was not a material impact to our consolidated financial statements as of and for the year ended March 31, 2023. Actual results could differ from estimates making it reasonably possible that a change in the estimates could occur in the near term. Revenue recognition In April 2016, the FASB issued ASU 2016–10 Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. The amendments in this Update do not change the core principle of the guidance in Topic 606. Rather, the amendments in this Update clarify the following two aspects of Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. Topic 606 includes implementation guidance on (a) contracts with customers to transfer goods and services in exchange for consideration and (b) determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). The amendments are intended to render more detailed implementation guidance with the expectation to reduce the degree of judgement necessary to comply with Topic 606. ASC Topic 606 prescribes a new five-step model entities should follow in order to recognize revenue in accordance with the core principle. These five steps are: 1. Identify the contract(s) with a customer. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. 4. Allocate the transaction price to the performance obligations in the contract. 5. Recognize revenue when (or as) the entity satisfied the performance obligations. The Company implemented the transition using the modified retrospective method of transition. The funds are not earned on milestones that have not been reached per the contract. Based on the cut off treatment of the recognition of revenue per the milestones specific to the license agreements, the Company has determined that there are no adjustments in the value of the revenue recognized from these contracts. The Company had one revenue stream, which is the milestone payments of the license agreement with BioRay Pharmaceutical which is not earned or billed until the milestone per the agreement is met. Accounts receivable Accounts receivable are carried at face value less any provisions for uncollectible amounts. Accounts receivable are receivables from a license agreement. No allowance for bad debt was considered necessary for the years ended March 31, 2023 and 2022, respectively. Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the fair value recognition provision of the Financial Accounting Standards Board(“FASB”) Accounting Standards Codification (“ASC”) No 718. The Company issues restricted stock to employees and consultants for their services. Cost of these transactions are measured at fair value of the equity instrument issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as the expense in the period granted. The Company recognized consulting expense and a corresponding increase to the additional paid in capital related to the stock issued for services. For agreements requiring future services the consulting expense is to be recognized ratably over the requisite service period. Research and Development Expense Research and development costs are expensed in the period they are incurred in accordance with ASC 730, Research and Development unless they meet specific criteria related to technical, market and financial feasibility, as determined by management, including but not limited to the establishment of a clearly defined future alternative use for the product, and the availability of adequate resources to complete the project. If all criteria are met, the costs are deferred and amortized over the expected useful life of the project or expensed as research and development as the material are consumed or written off if a product is abandoned. At March 31, 2023 and 2022, the Company had zero capitalization associated with materials held with a future alternative use. The cost of these materials was expensed as research and development as the materials are consumed or designated for usage. As the Company is preparing to begin clinical studies using a dose escalation method, it is not feasible to determine if the additional product will be needed for the brain cancer studies. Property and Equipment Property and equipment is recorded at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the expected useful life of the asset (3 to 5 years), beginning when the asset is available and ready for use. Expenditures associated with upgrades and enhancements that improve, add functionality, or otherwise extend the life of property and equipment are capitalized, while expenditures that do not, such as repairs and maintenance, are expensed as incurred. For the years ended March 31, 2023 and 2022, depreciation expense totaled zero, respectively. Impairment of Long-Lived Assets The Company reviews the carrying value of its long-lived assets annually or whenever events or changes in circumstances indicate that the historical-cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the asset by comparing the undiscounted future net cash flows expected to result from the asset to its carrying value. If the carrying value exceeds the undiscounted future net cash flows of the asset, an impairment loss is measured and recognized. An impairment loss is measured as the difference between the net book value and the fair value of the long-lived asset. Fair value is estimated based upon either discounted cash flow analysis or estimated salvage value. There was no impairment recognized during the years ended March 31, 2023 and 2022. Income Taxes Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company accounts for income taxes under the provisions of FASB ASC 740, Accounting for Income Taxes Basic and Diluted Net Income (Loss) per Share Basic net income (loss) per share calculations are calculated on the basis of the weighted average number of common shares outstanding during the year. During the year ended March 31, 2023 the Company had a net loss so the options and warrants outstanding were not part the loss per share calculation as they would be antidilutive. Diluted income (loss) per share calculations includes the dilutive effect of warrants and options on the weighted average of the per share calculation. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, accounts payable and accrued expenses and shareholder loans. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. As defined in (Financial Accounting Standards Board ASC 820), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilized the market data of similar entities in its industry or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. FASB ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The three levels of the fair value hierarchy are as follows: Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities, and listed equities. Level 2 – Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date and includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options, and collars. Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value. As of March 31, 2023, the Company believes the amounts reported for cash, payables, accrued liabilities and amounts due to related parties approximate their fair values due to the nature or duration of these instruments. The following table represents the change in the fair value of the derivative liabilities during the year ended March 31, 2023: Level 1 Level 2 Level 3 Fair value of derivative liability as of March 31, 2021 $ - $ - $ 302,156 Change in fair value at initial issuance - - 166,667 Change in fair value of the derivative - - (468,823 ) Balance at March 31, 2022 $ - $ - $ - Change in fair value at initial issuance and conversion - - 178,739 Change in fair value at conversion (570,099 ) Change in fair value of the derivative - - 1,054,786 Balance at March 31, 2023 $ - $ - $ 663,426

GOING CONCERN

GOING CONCERN	12 Months Ended
	Mar. 31, 2023
GOING CONCERN
NOTE 3 - GOING CONCERN	NOTE 3 – GOING CONCERN The Company’s consolidated financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company, as shown in the accompanying consolidated balance sheets, has working capital deficit of $1,296,137 and an accumulated deficit of $21,622,775 as of March 31, 2023. The Company does not have a source of revenue to cover its operating costs. These factors raise substantial doubt about the company’s ability to continue as a going concern. The Company will engage in research and development activities that must be satisfied in cash secured through outside funding. The Company will offer noncash consideration and seek equity lines as a means of financing its operations. If the Company is unable to obtain revenue producing contracts or financing or if the revenue or financing it does obtain is insufficient to cover any operating losses it may incur, it may substantially curtail or terminate its operations or seek other business opportunities through strategic alliances, acquisitions or other arrangements that may dilute the interests of existing stockholders.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Mar. 31, 2023
RELATED PARTY TRANSACTIONS
NOTE 4 - RELATED PARTY TRANSACTIONS	NOTE 4– RELATED PARTY TRANSACTIONS On September 1, 2020, the Company entered five-year compensation agreements with two of its officers and an independent director. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company. In addition, the officers ae entitled to future bonuses including a signing bonus totaling $170,000 plus additional bonuses based on their performance. Officer and Director Fiscal Year Annualized Compensation Base Being Paid Non-dilutive shares percentage President and CEO (2) $ 252,000 12 % Chief Financial Officer (1) $ 180,000 6 % Director (3) $ 20,000 - Total $ 452,000 18 % For the year ended March 31, 2023: (1) The Chief Financial Officers was paid $180,000 in cash. (2) The President and Chief Executive Officer was paid $252,000. (3) The director of the Company was paid $20,000 in director fees which was paid in stock. The following table sets forth the shares earned under these contracts from inception through year ended March 31, 2023: Officer and Director Initial Share Awards Under the Contracts Additional Shares Earned to Maintain Ownership Percentage Total Shares Earned President 1,028,910 10,052,269 11,081,179 Chief Financial Officer 617,346 5,258,723 5,876,069 Total 1,646,256 15,310,992 16,957,248 As of March 31, 2023, the Company had zero due to officers and directors. In December 2021, an officer of the Company advanced the Company $21,220, $14,220 for accounts payable and $7,000 in cash. The Company repaid the advance on February 9, 2022. During the year ended March 31, 2022 two officers and a director converted $128,333 of accrued payables into 2,407,010 shares of common stock. During the year ended March 31, 2022 the Company issued 1,513,719 shares of common stock with a value of $110,835 to three related parties for service. During the year ended March 31, 2023 the Company issued 3,815,414 shares of common stock with a value of $624,320 to three related parties for service.

LICENSE SETTLEMENT

LICENSE SETTLEMENT	12 Months Ended
	Mar. 31, 2023
LICENSE SETTLEMENT
NOTE 5 - LICENSE SETTLEMENT	NOTE 5 – LICENSE SETTLEMENT On October 12, 2017, the Company signed a consulting agreement with a former license holder. Under the terms of the agreement the Company, commencing February 1, 2018 will pay the consultant $1,000 per month for 24 months. In addition, the Company will pay the consultant an additional $24,000 during the term of the agreement at the Company’s discretion. In return, the consultant forgave all royalty payments plus any past claims to the product per the previous agreement dated September 21, 2015, plus provide consulting services to the Company as directed by the Company. As of September 20, 2022 the consultant was paid in full.

EQUITY

EQUITY	12 Months Ended
	Mar. 31, 2023
EQUITY
NOTE 6 - EQUITY	NOTE 6 – EQUITY On July 9, 2020, the Company increased its authorized shares to 550,000,000 consisting of 50,000,000 preferred shares and 500,000,000 common shares all at par value $0.001. Preferred Stock On July 10, 2019, the Company filed an amended articles of Incorporation designating 1,500,000 shares of preferred stock as Series A non-voting Convertible preferred shares convertible into common stock at four shares of common for each one share of preferred. During the year ended March 31, 2021 the Company issued 740,000 shares of Series A preferred stock and 3,700,000 warrants; 640,000 for $640,000 in cash and $100,000 for debt. The stock is convertible into common stock at 10 cents per share or 50% of the lowest trading price, whichever is lower 5 days prior to conversion. The Company has the right to convert the shares nine months after the issuance. The warrants are convertible at $0.15 per share within two years of issuance. In addition the Company agreed to filing an S-1 for the common stock to be converted and the underlying common shares for the warrants. During the year ended March 31, 2022 the Company issued 1,968,363 shares of common stock for the conversion of 54,130 shares of preferred stock. As of March 31, 2023 and 2022 there we no outstanding preferred shares. Common Stock During the year ended March 31, 2022 two officers and a director converted $128,333 of accrued payables into 2,407,010 shares of common stock. During the year ended March 31, 2022 the Company issued 540,000 shares of Common stock to an individual for account payable with a value of $27,000. During the year ended March 31, 2022 the Company issued 50,000 shares of common stock with a value of $5,250 for service. During the year ended March 31, 2022 the Company issued 1,968,363 shares of common stock for the conversion of 54,130 shares of preferred stock. During the year ended March 31, 2022 the Company issued 1,513,719 shares of common stock with a value of $110,835 to three related parties for service. During the year ended March 31, 2023 the Company issued 37,700 shares of common stock with a value of $9,275 for accounts payable. During the year ended March 31, 2023, the Company issued 1,000,000 shares of common stock for clinical consulting with a value of $60,000. During the year ended March 31, 2023, the Company 4,200,000 shares of common stock for the conversion of 4,200,000 warrants with a value of $208,000 received in cash. During the year ended March 31, 2023 , the Company issued 3,815,414 shares of common stock with a value of $624,320 to three related parties for service. During the year ended March 31, 2023 the Company issued 11,398,059 shares of common stock with a value of $1,023,975 for the conversion of debt and accrued interest.

OPTIONS

OPTIONS	12 Months Ended
	Mar. 31, 2023
OPTIONS
NOTE 7 - OPTIONS	NOTE 7 – OPTIONS The Company under its 2015 option plan issues options to various officers, directors, and consultants. The options vest in equal annual installments over a five year period with the first 20% vested when the options were granted. All of the options are exercisable at a purchase price based on the last trading price of the Company’s common stock on the date of grant and have a term of 10 years. On April 1, 2016, the Company issued 40,000 options to a consultant under the 2015 option program. The options are exercisable into the Company’s common stock at $0.30 per share, have term of 10 years and vest in 5 equal annual installments with the first installment vesting on the date of grant. This award to a nonemployee is revalued at each reporting period until completion of services. On April 1, 2016, the Company entered a consulting agreement under which the consultant was granted 30,000 options. In addition, the consultant received additional option grants of 30,000 options on April 1, 2017 and 40,000 options on April 1, 2018. The options are exercisable into the Company’s common stock at $0.30 per share, have term of 10 years and vest in 5 equal annual installments with the first installment vesting on the date of grant. On July 20, 2016, the Company granted from the 2015 Option Program 300,000 options each to three officers and directors for a total of 900,000 options being granted. The options are exercisable into the Company’s common stock at an exercise price of $0.301 per share and were vested and expensed at the date of issuance. The fair value at date of granted was determined to be $484,205. On April 1, 2018, the Company granted from the 2015 Option Program 40,000 options to one consultant. The options are exercisable into the Company’s common stock at an exercise price of $0.25 per share and were vested and expensed at the date of issuance. The fair value at date of granted was determined to be $9,991. On November 17, 2022 the Company issued 500,000 options to one individual with an exercise price of $0.18 per share. The options have a 5 year life and vested 250,000 options at inception and 25,000 options per month thereafter until fully vested. The options were fair valued using a volatility of 250%, discount rate of 4.35% at $114,531 to be amortized over the 5 year period. During the years ended March 31, 2023 and 2022, the Company expensed $72,000 and zero, respectively related to its option awards. The unrecognized future balance to be expensed over the remaining vesting term of the options is 26,219 as of March 31, 2023. The following sets forth the options granted and outstanding during the years ended March 31, 2023 and 2022: Options Weighted Average Exercise Price Weighted Average Remaining Contract Life Number of Options Exercisable Intrinsic Value Outstanding at March 31, 2021 1,405,000 $ 0.34 4.80 1,405,000 $ - Granted - - - - - Exercised - - - - - Forfeited (475,000 ) - (475,000 ) - Outstanding at March 31, 2022 930,000 $ 0.34 3.80 930,000 $ - Granted 500,000 0.18 4.75 - - Exercised - - - - - Forfeited - - - - -- Outstanding at March 31, 2023 1,430,000 $ 0.28 3.81 930,000 $ -

WARRANTS

WARRANTS	12 Months Ended
	Mar. 31, 2023
WARRANTS
NOTE 8 - WARRANTS	NOTE 8 – WARRANTS During the year ended March 31, 2021, the Company granted 3,700,000 warrants to four entities as part of the issuance of 740,000 Series A convertible preferred shares. The warrants expire in two years from grant date and are convertible into common stock at $0.15 per share. The warrants contain an anti-dilution clause which become effective if any instrument is issued after the warrant issuance is converted into common stock at a price lower than the warrant conversion price. The Company used the Black Scholes Pricing model to estimate the fair value of the warrants as of grant date, using the following key inputs: market prices of the Company’s common stock at dates of grant between $0.08-0.11 per share, conversion price of $0.15, volatility of 312.5%-314.49% and discount rate of 0.14-0.16%. Based on the fair value of the common stock of $437,000 and value of the warrants of $349,605 the fair value of the warrants was calculated to be 41% of the total value or $303,000. During the year ended March 31, 2021 the valuation resulted in a deemed dividend from the down round calculation of $555,000 with a recalculated conversion price change to $0.04 per share. On April 7, 2022, the Company issued 500,000 warrants as part of a convertible note issued the same date. The Company used the Black Scholes Pricing model to estimate the fair value of the warrants as of grant date using the following key inputs; market prices of the Company’s stock at date of grant of $0.08 per share, conversion price of $0.12 per share, volatility of 132% and discount of 1.78%. The fair value of the warrants were calculated to be $ 26,000 and was used to allocate the proceeds to the two elements based on the relative fair value of the debt instruments without the warrants and of the warrants at the time of issuance. The portion of the proceeds were allocated to the warrants of $21,336 is accounted for as paid in capital. As of March 31, 2023 the 500,000 warrants were converted into 500,000 shares of common stock with a value of $60,000. On August 31, 2022 the Company issued 750,000 warrants as part of a convertible note issued the same date. The Company used the Black Scholes Pricing model to estimate the fair value of the warrants as of grant date using the following key inputs; market prices of the Company’s stock at date of grant of $0.41 per share, conversion price of $0.60 per share, volatility of 137% and discount of 3.50%. The fair value of the warrants were calculated to be $ 188,760 and was used to allocate the proceeds to the two elements based on the relative fair value of the debt instruments without the warrants and of the warrants at the time of issuance. The portion of the proceeds that were allocated to the warrants of $9,902 is accounted for as paid in capital. On September 2, 2022 the Company issued 250,000 warrants as part of a convertible note issued the same date. The Company used the Black Scholes Pricing model to estimate the fair value of the warrants as of grant date using the following key inputs; market prices of the Company’s stock at date of grant of $0.345 per share, conversion price of $0.60 per share, volatility of 137% and discount of 3.47%. The fair value of the warrants were calculated to be $50,273 and was used to allocate the proceeds to the two elements based on the relative fair value of the debt instruments without the warrants and of the warrants at the time of issuance. The portion of the proceeds were allocated to the warrants of $2,484 is accounted for as paid in capital. The weighted average remaining life and intrinsic value of the warrants as of March 31, 2023 was. Warrants Weighted Average Exercise Price Weighted Average Remaining Contract Life Intrinsic Value Outstanding at March 31, 2021 - $ 0.00 0.00 $ - Granted 3,700,000 0.15 2.00 Exercised - - - Expired - - - Outstanding at March 31, 2022 3,700,000 $ 0.04 1.35 $ - Granted 1,000,000 0.60 1.75 - Exercised (3,700,000 ) - - Expired - - - Outstanding at March 31, 2023 1,000,000 $ 0.60 1.50 $ - As of March 31, 2023 there were 1,000,000 warrants outstanding.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Mar. 31, 2023
INCOME TAXES
NOTE 9 - INCOME TAXES	NOTE 9 – INCOME TAXES At March 31, 2023 and 2022, the Company had federal net operating loss carry forwards of approximately $13,544,358 and $11,786,575 respectively. Components of net deferred tax assets, including a valuation allowance, are as follows at March 31, 2023 and 2022: March 31, 2023 March 31, 2022 Deferred tax assets: Net operating loss $ 1,757,783 $ 319,880 Less: Valuation allowance (1,757,783 ) (319,880 ) Net deferred tax assets $ - $ - In assessing the recovery of the deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in the periods in which those temporary differences become deductible. Management considers the scheduled reversals of future deferred tax assets, projected future taxable income, and tax planning strategies in making this assessment. As a result, management determined it was more likely than not the deferred tax assets would not be realized as of March 31, 2023. Based on the recent change in corporation tax rates the Company calculated the deferred tax asset for the years ended March 31, 2023 and 2022 at 21%. The Company, due to its losses, has not filed US Corporate tax returns and is subject to examination back to March 31, 2015.

CONVERTIBLE DEBT

CONVERTIBLE DEBT	12 Months Ended
	Mar. 31, 2023
CONVERTIBLE DEBT
NOTE 10 - CONVERTIBLE DEBT	NOTE 10 – CONVERTIBLE DEBT On May 7, 2020, The Company issued an 8% $50,000 one year convertible note. The note was convertible into common stock at the lesser of $0.20 per share or 80% of the lowest closing bid five days prior to conversion. On July 7, 2020, $50,000 of the one year convertible note payable was converted into 50,000 shares of series A preferred. On October 28, 2020, the Company issued a $138,000 convertible note with an OID of $10,000. The note matures on October 28, 2021 and bears interest at 10% per annum. After 180 days the note may be converted into common stock of the Company at $0.04 per share or a 30% discount to the VWAP during the 20 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 212% and expected life of .50 years. On April 20, 2021, note was paid with the principal of $138,000, accrued interest of $6,805 and financing costs of $41,400. On November 11, 2020, the Company issued a $82,500 convertible note with an OID of $7,500. The note matures on October 28,2021 with a fixed interest of 10%. After 180 days the note may be converted into common stock of the Company at a 35% discount to the lowest trading price during the 20 days prior to conversion. On April 22, 2021, the note was paid consisting of principal of $82,500, accrued interest of $8,250 and finance costs of $24,750. On August 10, 2021, the Company issued a $200,000 convertible note. The note matures on February 10, 2022, and bears fixed interest of 10%. Within 180 days of issuance the note may be repaid at an escalating premium up to 125% of the face value of the note. After 180 days the note may be converted into common stock of the Company at $0.06 per share or a 25% discount to the lowest trading price during the 10 days prior to conversion. The initial derivative was calculated using risk free interest of .05%, volatility of 132% and expected life of 0.50 years. On March 28, 2022, the Note was paid consisting of $200,000 in principal, accrued interest of $997,260 and financing costs of $50,000. On April 7, 2022, the Company issued a $275,000 convertible note with an OID of $25,000. The note matures on March 29, 2023, bears fixed interest of 8% plus contains a most favored nations statement. Within 180 days of issuance, the note may be repaid at a premium of 115% of the face value of the note and 150% of the unconverted balance of the note after 180 days and prior to maturity. After 180 days the note may be converted into common stock of the Company at $0.075 per share or a 20% discount to the lowest VWAP (Volume- Weighted Average Pricing) price during the 10 days prior to conversion. The initial derivative was calculated using risk free interest of .05%, volatility of 132% and expected life of 0.50 years. On September 9, 2022 the note was paid with the note principal of $275,000, interest of $9,162 and premium of $42,624 for a total of $326,786. On August 31, 2022 the Company entered into an agreement with an unrelated third party for convertible debentures totaling $1,500,000. The first $500,000 was paid at closing with the second $500,000 paid on September 20, 2022, upon filing of an S-1 Registration, and the third $500,000 paid on September 27, 2022, upon the S-1 becoming effective. Each debenture matures one year from date of issuance. The interest rate for each debenture is six percent (6%) per annum and the Debenture may be converted at the lesser of $0.30 per share or eighty percent (80%) of the lowest VWAP of the Company’s common stock for ten consecutive trading days immediately prior to the conversion date and carried an original discount of 3% of the debenture face value. The Company also issued a warrant to purchase 750,000 shares of the Company’s common stock for a period of two years, expiring on August 30, 2024, at an exercise price of $0.60 per share. As part of the agreement the Company filed an S-1 registration statement registering the underlying common shares for the debenture conversion and the warrants. The initial derivatives were calculated for each debenture as follows: 1. Debenture 1- risk free interest of 3.50%, volatility of 137% and expected life of 1.00 years 2. Debenture 2- risk free interest of 4.03%, volatility of 140% and expected life of 1.00 years 3. Debenture 3- risk free interest of 3.98%, volatility of 141% and expected life of 1.00 years During the period ended March 31, 2023, the Company issued 9,539,197 shares of common stock with a value of $823,975 for the conversion of $800,000 of convertible note and $23,975 in interest, leaving a balance due of $700,000 of convertible notes plus accrued interest. On September 2, 2022 the Company entered into an agreement with an unrelated third party for convertible debentures totaling $500,000. The first $250,000 was paid at closing with the second $250,000 to be paid upon the S-1 becoming effective. Each debenture matures one year from date of issuance. The interest rate for each debenture is six percent (6%) per annum and the Debenture may be converted at the lesser of $0.30 per share or eighty percent (80%) of the lowest VWAP of the Company’s common stock for ten consecutive trading days immediately prior to the conversion date and carried an original discount of 3% of the debenture face value. The Company also issued a warrant to purchase 250,000 shares of the Company’s common stock for a period of two years, expiring on August 30, 2024, at an exercise price of $0.60 per share. As part of the agreement the Company filed an S-1 registration statement registering the underlying common shares for the debenture conversion and the warrants. The initial derivative was calculated using risk free interest of 3.47%, volatility of 137% and expected life of 1 year. As of March 31, 2023 the funds for the second debenture had not been received. During the year ended March 31, 2023, the Company issued 1,858,862 shares of common stock for the conversion of $200,000 of the convertible note leaving a balance of $50,000 plus accrued interest. As of March 31, 2023 the second $250,00 had not been paid to the Company.

LICENSE AGREEMENT

LICENSE AGREEMENT	12 Months Ended
	Mar. 31, 2023
LICENSE AGREEMENT
NOTE 11 - LICENSE AGREEMENT	NOTE 11- LICENSE AGREEMENT On March 31, 2021, the Company issued a license agreement for US $5,000,000 to BioRay Pharmaceutical Co, LTD, (Licensee) licensing Pritumumab internationally with the exclusion of North and Central America and the Caribbean Islands. Under the terms of the agreement the Company receives $250,000 upon signing of the agreement plus $750,000 with the start of the phase 1 clinical trials , which started in March 2021. In addition, the Company received $750,000 upon the initial patient enrolled at the dosage level of 8.0 mg/kg. Further payment of $2,500,000 will be received when the FDA approves the phase 2 clinical trials and $750,000 when the phase 2 clinical trials begin. Upon commercialization by the Licensee, the Company will receive a 9% royalty on net sales for 20 years. As of March 31, 2023 the Company received payments totaling $1,750,000 from the license. (See Note 13- Subsequent Events)

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Mar. 31, 2023
COMMITMENTS AND CONTINGENCIES
NOTE 12 - COMMITMENTS AND CONTINGENCIES	NOTE 12 –COMMITMENTS AND CONTINGENCIES On June 30, 2016, the Company entered into a cell line sales agreement with the product manufacture. Under the terms of the agreement the company is obligated to make future payments based on the milestones of its achievements. These future payments may be as followed; 1. $100,000 upon the initiation (first dose/first patient) of the first Phase I clinical trial (or equivalent) of a product. 2. $225,000 upon the initiation (first dose/first patient) of the first Phase III clinical trial (or equivalent) of a product. 3. $225,000 payable upon the first BLA approval (or equivalent) of a product. 4. Annual maintenance fee upon completion of phase I manufacturing or the transfer of the cell line from Catalent’s control of $50,000. 5. A contingent sales fee upon product sales of 1% of sales or $150,000 whichever is greater. As of March 31, 2023 the outstanding amount due the manufacture was $19,300. On March 9, 2020, the Board of Directors of the Company adapted an expense bonus program. Under the program, if an acquisition, merger or change in control is affected, 10% of the value of the transaction will be allocated to pay the expenses of the transaction including but not limited to legal, accounting, transfer fees and other miscellaneous expense. The balance of the fund after expenses will be allocation 20% to directors and 80% to officers and employees of the Company as allocated by the Chief Executive Officer and approved by the Board of Directors. On September 1, 2020, the Company entered five-year compensation agreements with two of its officers and directors. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Mar. 31, 2023
SUBSEQUENT EVENTS
NOTE 13 - SUBSEQUENT EVENTS	NOTE 13 SUBSEQUENT EVENTS On May 1, 2023 the Company issued 3,837,419 shares of common stock with a value of $151,578 for the conversion of $150,000 of convertible debt and $1,578 in accrued interest. On May 17, 2023 the Company issued 1,331,919 shares of common stock with a value of $50,240 for the conversion of $45,000 of convertible debt and $5,240 in accrued interest. On May 24, 2023 the Company issued 4,367,842 shares of common stock with a value of $165,978 for the conversion of $150,000 of convertible debt and $15,978 in accrued interest. On June 6, 2023 the Company signed a mutual agreement with BioRay Pharmaceutical Co to terminate the license agreement, dated March 31, 2021. The termination of the agreement rescinds all rights by BioRay and returns to the Company, the global rights, which had been granted BioRay under the agreement. On May 30, 2023 the Company issued 100,000 shares with a value of $5,600 to one individual for service. The Company has evaluated subsequent events to determine events occurring after March 31, 2023 through the date this report was issued there are not events that would have a material impact on the Company’s financial results or require disclosure and have determined none exist other than those noted above in this footnote.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Mar. 31, 2023
SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation	The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. The Company has elected a fiscal year ending on March 31.
Principle of consolidation	The accompanying consolidated financial statements include the accounts of Nascent Biotech, Inc. and its wholly-owned subsidiary Nascent Biologics, Inc, which has been inactive since March 2015. All intercompany accounts and transactions have been eliminated.
Cash and Cash Equivalents	The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company as of March 31, 2023 did not have any cash equivalents.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the periods. The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition, and results of operations is highly uncertain and subject to change. We considered the potential impact of the COVID-19 pandemic on our estimates and assumptions and there was not a material impact to our consolidated financial statements as of and for the year ended March 31, 2023. Actual results could differ from estimates making it reasonably possible that a change in the estimates could occur in the near term.
Revenue recognition	In April 2016, the FASB issued ASU 2016–10 Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. The amendments in this Update do not change the core principle of the guidance in Topic 606. Rather, the amendments in this Update clarify the following two aspects of Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. Topic 606 includes implementation guidance on (a) contracts with customers to transfer goods and services in exchange for consideration and (b) determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). The amendments are intended to render more detailed implementation guidance with the expectation to reduce the degree of judgement necessary to comply with Topic 606. ASC Topic 606 prescribes a new five-step model entities should follow in order to recognize revenue in accordance with the core principle. These five steps are: 1. Identify the contract(s) with a customer. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. 4. Allocate the transaction price to the performance obligations in the contract. 5. Recognize revenue when (or as) the entity satisfied the performance obligations. The Company implemented the transition using the modified retrospective method of transition. The funds are not earned on milestones that have not been reached per the contract. Based on the cut off treatment of the recognition of revenue per the milestones specific to the license agreements, the Company has determined that there are no adjustments in the value of the revenue recognized from these contracts. The Company had one revenue stream, which is the milestone payments of the license agreement with BioRay Pharmaceutical which is not earned or billed until the milestone per the agreement is met.
Accounts receivable	Accounts receivable are carried at face value less any provisions for uncollectible amounts. Accounts receivable are receivables from a license agreement. No allowance for bad debt was considered necessary for the years ended March 31, 2023 and 2022, respectively.
Stock-Based Compensation	The Company accounts for stock-based compensation in accordance with the fair value recognition provision of the Financial Accounting Standards Board(“FASB”) Accounting Standards Codification (“ASC”) No 718. The Company issues restricted stock to employees and consultants for their services. Cost of these transactions are measured at fair value of the equity instrument issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as the expense in the period granted. The Company recognized consulting expense and a corresponding increase to the additional paid in capital related to the stock issued for services. For agreements requiring future services the consulting expense is to be recognized ratably over the requisite service period.
Research and Development Expense	Research and development costs are expensed in the period they are incurred in accordance with ASC 730, Research and Development unless they meet specific criteria related to technical, market and financial feasibility, as determined by management, including but not limited to the establishment of a clearly defined future alternative use for the product, and the availability of adequate resources to complete the project. If all criteria are met, the costs are deferred and amortized over the expected useful life of the project or expensed as research and development as the material are consumed or written off if a product is abandoned. At March 31, 2023 and 2022, the Company had zero capitalization associated with materials held with a future alternative use. The cost of these materials was expensed as research and development as the materials are consumed or designated for usage. As the Company is preparing to begin clinical studies using a dose escalation method, it is not feasible to determine if the additional product will be needed for the brain cancer studies.
Property and Equipment	Property and equipment is recorded at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the expected useful life of the asset (3 to 5 years), beginning when the asset is available and ready for use. Expenditures associated with upgrades and enhancements that improve, add functionality, or otherwise extend the life of property and equipment are capitalized, while expenditures that do not, such as repairs and maintenance, are expensed as incurred. For the years ended March 31, 2023 and 2022, depreciation expense totaled zero, respectively.
Impairment of Long-Lived Assets	The Company reviews the carrying value of its long-lived assets annually or whenever events or changes in circumstances indicate that the historical-cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the asset by comparing the undiscounted future net cash flows expected to result from the asset to its carrying value. If the carrying value exceeds the undiscounted future net cash flows of the asset, an impairment loss is measured and recognized. An impairment loss is measured as the difference between the net book value and the fair value of the long-lived asset. Fair value is estimated based upon either discounted cash flow analysis or estimated salvage value. There was no impairment recognized during the years ended March 31, 2023 and 2022.
Income Taxes	Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company accounts for income taxes under the provisions of FASB ASC 740, Accounting for Income Taxes
Basic and Diluted Net Income (Loss) per Share	Basic net income (loss) per share calculations are calculated on the basis of the weighted average number of common shares outstanding during the year. During the year ended March 31, 2023 the Company had a net loss so the options and warrants outstanding were not part the loss per share calculation as they would be antidilutive. Diluted income (loss) per share calculations includes the dilutive effect of warrants and options on the weighted average of the per share calculation.
Fair Value of Financial Instruments	The Company’s financial instruments consist of cash and cash equivalents, accounts payable and accrued expenses and shareholder loans. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. As defined in (Financial Accounting Standards Board ASC 820), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilized the market data of similar entities in its industry or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. FASB ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The three levels of the fair value hierarchy are as follows: Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities, and listed equities. Level 2 – Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date and includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options, and collars. Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value. As of March 31, 2023, the Company believes the amounts reported for cash, payables, accrued liabilities and amounts due to related parties approximate their fair values due to the nature or duration of these instruments. The following table represents the change in the fair value of the derivative liabilities during the year ended March 31, 2023: Level 1 Level 2 Level 3 Fair value of derivative liability as of March 31, 2021 $ - $ - $ 302,156 Change in fair value at initial issuance - - 166,667 Change in fair value of the derivative - - (468,823 ) Balance at March 31, 2022 $ - $ - $ - Change in fair value at initial issuance and conversion - - 178,739 Change in fair value at conversion (570,099 ) Change in fair value of the derivative - - 1,054,786 Balance at March 31, 2023 $ - $ - $ 663,426

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Mar. 31, 2023
SIGNIFICANT ACCOUNTING POLICIES
Schedule of Summarizes of change in the fair value of the derivative liabilities	Level 1 Level 2 Level 3 Fair value of derivative liability as of March 31, 2021 $ - $ - $ 302,156 Change in fair value at initial issuance - - 166,667 Change in fair value of the derivative - - (468,823 ) Balance at March 31, 2022 $ - $ - $ - Change in fair value at initial issuance and conversion - - 178,739 Change in fair value at conversion (570,099 ) Change in fair value of the derivative - - 1,054,786 Balance at March 31, 2023 $ - $ - $ 663,426

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Mar. 31, 2023
RELATED PARTY TRANSACTIONS
Schedule of annual salary and annual severance amounts	Officer and Director Fiscal Year Annualized Compensation Base Being Paid Non-dilutive shares percentage President and CEO (2) $ 252,000 12 % Chief Financial Officer (1) $ 180,000 6 % Director (3) $ 20,000 - Total $ 452,000 18 %
Schedule of shares earned by related party	Officer and Director Initial Share Awards Under the Contracts Additional Shares Earned to Maintain Ownership Percentage Total Shares Earned President 1,028,910 10,052,269 11,081,179 Chief Financial Officer 617,346 5,258,723 5,876,069 Total 1,646,256 15,310,992 16,957,248

OPTIONS (Tables)

OPTIONS (Tables)	12 Months Ended
	Mar. 31, 2023
OPTIONS
Schedule of Summary of stock options aoutstanding	Options Weighted Average Exercise Price Weighted Average Remaining Contract Life Number of Options Exercisable Intrinsic Value Outstanding at March 31, 2021 1,405,000 $ 0.34 4.80 1,405,000 $ - Granted - - - - - Exercised - - - - - Forfeited (475,000 ) - (475,000 ) - Outstanding at March 31, 2022 930,000 $ 0.34 3.80 930,000 $ - Granted 500,000 0.18 4.75 - - Exercised - - - - - Forfeited - - - - -- Outstanding at March 31, 2023 1,430,000 $ 0.28 3.81 930,000 $ -

WARRANTS (Tables)

WARRANTS (Tables)	12 Months Ended
	Mar. 31, 2023
WARRANTS
Schedule of Summary of warrants outstanding	Warrants Weighted Average Exercise Price Weighted Average Remaining Contract Life Intrinsic Value Outstanding at March 31, 2021 - $ 0.00 0.00 $ - Granted 3,700,000 0.15 2.00 Exercised - - - Expired - - - Outstanding at March 31, 2022 3,700,000 $ 0.04 1.35 $ - Granted 1,000,000 0.60 1.75 - Exercised (3,700,000 ) - - Expired - - - Outstanding at March 31, 2023 1,000,000 $ 0.60 1.50 $ -

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Mar. 31, 2023
INCOME TAXES
Schedule of Components of net deferred tax assets	March 31, 2023 March 31, 2022 Deferred tax assets: Net operating loss $ 1,757,783 $ 319,880 Less: Valuation allowance (1,757,783 ) (319,880 ) Net deferred tax assets $ - $ -

ORGANIZATION AND NATURE OF OP_2

ORGANIZATION AND NATURE OF OPERATIONS (Details Narrative) - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Jul. 15, 2014
Common stock, outstanding shares	131,764,348	111,313,175
Jin-En [Member]
Common stock, issued shares			7,500,200
Common stock, shares cancelled			15,000,000
Common stock, outstanding shares			22,829,400
Net liablilities			$ 19,000

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Level 1 [Member]
Begnning Balance	$ 0	$ 0
Change in fair value at initial issuance	0	0
Change in fair value at initial issuance and conversion	0
Change in fair value of the derivative	0	0
Ending Balance	0	0
Level 2 [Member]
Begnning Balance	0	0
Change in fair value at initial issuance	0	0
Change in fair value at initial issuance and conversion	0
Change in fair value of the derivative	0	0
Ending Balance	0	0
Level 3 [Member]
Begnning Balance	0	302,156
Change in fair value at initial issuance		166,667
Change in fair value at initial issuance and conversion	178,739
Change in fair value of the derivative	1,054,786	(468,823)
Ending Balance	663,426	$ 0
Change in fair value at conversion	$ (570,099)

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Depreciation expense	$ 0	$ 0
Minimum [Member]
Expected life in years	3 years
Maximum [Member]
Expected life in years	5 years

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative)	Mar. 31, 2023 USD ($)
GOING CONCERN
Working capital deficit	$ (1,296,137)
Accumulated Deficit	$ (21,622,775)

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details)	12 Months Ended
	Mar. 31, 2023 USD ($)
Fiscal Year Annualized Compensation Being Paid	$ 452,000
Non-dilutive shares, percentage	18%
President [Member]
Fiscal Year Annualized Compensation Being Paid	$ 252,000
Non-dilutive shares, percentage	12%
Chief Financial Officer [Member]
Fiscal Year Annualized Compensation Being Paid	$ 180,000
Non-dilutive shares, percentage	6%
Director [Member]
Fiscal Year Annualized Compensation Being Paid	$ 20,000
Non-dilutive shares, percentage	0%

RELATED PARTY TRANSACTIONS (D_2

RELATED PARTY TRANSACTIONS (Details 1)	12 Months Ended
	Mar. 31, 2023 shares
Initial Share Awards Under the Contracts	1,646,256
Additional Shares Earned to Maintain Ownership Percentage	15,310,992
Total Shares Earned	16,957,248
President [Member]
Initial Share Awards Under the Contracts	1,028,910
Additional Shares Earned to Maintain Ownership Percentage	10,052,269
Total Shares Earned	11,081,179
Chief Financial Officer [Member]
Initial Share Awards Under the Contracts	617,346
Additional Shares Earned to Maintain Ownership Percentage	5,258,723
Total Shares Earned	5,876,069

RELATED PARTY TRANSACTIONS (D_3

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021
Cash			$ 7,000
Advanced payment			21,220
Common stock shares issued for services, amount	$ 624,320	$ 110,835
Common stock shares issued for services, shares	3,815,414	1,513,719
Accounts payable			$ 14,220
September 1, 2020 [Member]
Officers and directors employment agreement terms, description	Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company
Bonus amount	$ 170,000
Chief Financial Officers [Member]
Cash	180,000
President And Chief Executive Officer [Member]
Cash	252,000
Two Officers and Director [Member]
Common stock shares issued for services, amount		$ 128,333
Common stock shares issued for services, shares		2,407,010
Three Officers and Director [Member]
Accrued consulting fees	$ 20,000

LICENSE SETTLEMENT (Details Nar

LICENSE SETTLEMENT (Details Narrative) - Consulting agreement [Member]	Oct. 12, 2017 USD ($) integer
Number of installments, consideration for license | integer	24
Monthly installment payment	$ 1,000
Consulting fees payable	$ 24,000

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)				1 Months Ended		12 Months Ended
	Apr. 07, 2022	Aug. 10, 2021	Nov. 11, 2020	Feb. 16, 2021	Oct. 28, 2020	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Jul. 09, 2020	May 07, 2020	Jul. 10, 2019
Total no of authorized shares									550,000,000
Common stock shares value for services, amount						$ 624,320	$ 110,835
Preferred stock shares authorized						50,000,000	50,000,000		50,000,000
Common stock shares authorized						500,000,000	500,000,000		500,000,000
Common stock, par value						$ 0.001	$ 0.001		$ 0.001	$ 0.20
Preferred stock shares designated											1,500,000
Conversion of preferred stock shares issued							54,130
Preferred stock shares								$ 740,000
Common stock shares issued for services						3,815,414	1,513,719
Common stock shares value for account payable						37,700
Common stock shares, issued						131,764,348	111,313,175
Common stock, shares						4,200,000
Conversion of common stock into warrant						4,200,000
Warrant value of received in cash						$ 208,000
Clinical Consulting [Member]
Common stock shares issued for services						1,000,000
Common stock shares value for clinical consulting, amount						$ 60,000
Three Related Parties For Service [Member]
Common stock shares value for services, amount						$ 624,320
Common stock shares issued for services						3,815,414
Common stock shares value for related party						$ 624,320
Common Stock Two [Member]
Common stock shares value for services, amount							$ 110,835
Common stock shares issued for services							1,513,719
Series A Convertible Preferred Stock [Member]
Conversion of preferred stock shares issued							54,130
Common stock shares, issued							1,968,363
Conversion description	Within 180 days of issuance, the note may be repaid at a premium of 115% of the face value of the note and 150% of the unconverted balance of the note after 180 days and prior to maturity. After 180 days the note may be converted into common stock of the Company at $0.075 per share or a 20% discount to the lowest VWAP (Volume- Weighted Average Pricing) price during the 10 days prior to conversion. The initial derivative was calculated using risk free interest of .05%, volatility of 132% and expected life of 0.50 years	Within 180 days of issuance the note may be repaid at an escalating premium up to 125% of the face value of the note. After 180 days the note may be converted into common stock of the Company at $0.06 per share or a 25% discount to the lowest trading price during the 10 days prior to conversion. The initial derivative was calculated using risk free interest of .05%, volatility of 132% and expected life of 0.50 years	After 180 days the note may be converted into common stock of the Company at a 35% discount to the lowest trading price during the 20 days prior to conversion	After 180 days the note may be converted into common stock of the Company at a 30% discount to the lowest trading price during the 15 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 213% and expected life of 1.00 years	After 180 days the note may be converted into common stock of the Company at $0.04 per share or a 30% discount to the VWAP during the 20 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 212% and expected life of .50 years			The stock is convertible into common stock at 10 cents per share or 50% of the lowest trading price, whichever is lower 5 days prior to conversion. The Company has the right to convert the shares nine months after the issuance. The warrants are convertible at $0.15 per share within two years of issuance
Outstanding warrants, granted								3,700,000
Preferred stock issued for cash, shares								640,000
Debt							$ 100,000
Conversion Of Debt And Accrued Interest [Member]
Common stock shares value for services, amount						$ 1,023,975
Common stock shares issued for services						11,398,059
Preferred Stock
Common stock shares value for services, amount						$ 9,275
Two Officers and Director [Member]
Common stock shares value for services, amount							$ 128,333
Common stock shares issued for services							2,407,010
Accrued fees converted amount, shares							1,968,363
Two Officers and Director One [Member]
Common stock shares value for services, amount							$ 5,250
Common stock shares issued for services							50,000
Common stock shares value for account payable, amount							$ 27,000
Common stock shares value for account payable							540,000

OPTIONS (Details)

OPTIONS (Details) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Options
Number of option exercisable, Beginning	930,000	1,405,000
Outstanding option, Forfeited		(475,000)
Outstanding option, Granted	500,000
Number of option exercisable, Ending	1,430,000	930,000
Weighted average exercise price
Weighted average exercise price, Beginning	$ 0.34	$ 0.34
Weighted average exercise price granted	0.18
Weighted average exercise price, Ending	$ 0.28	$ 0.34
Weighted Average Remaining Contract Life
Weighted Average Remaining Contract life, Beginning	3 years 9 months 18 days	4 years 9 months 18 days
Weighted Average Remaining Contract life, granted	4 years 9 months
Weighted Average Remaining Contract life, Ending	3 years 9 months 21 days	3 years 9 months 18 days
Number of option exercisable
Outstanding option, Beginning	930,000	1,405,000
Outstanding option, Forfeited		(475,000)
Outstanding option, Ending	930,000	930,000
Intrinsic value
Intrinsic value, Beginning	$ 0	$ 0
Intrinsic value, Ending	$ 0	$ 0

OPTIONS (Details Narrative)

OPTIONS (Details Narrative)			1 Months Ended			12 Months Ended
	Sep. 02, 2022	Apr. 07, 2022	Nov. 17, 2022 USD ($) $ / shares shares	Aug. 31, 2022	Jul. 20, 2016 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) integer $ / shares shares	Mar. 31, 2022 USD ($)
Unrecognized future balance of vesting term option						26,219
Common stock exercisable term			5 years			10 years
Options vested description			The options have a 5 year life and vested 250,000 options at inception and 25,000 options per month thereafter until fully vested.			The options vest in equal annual installments over a five year period with the first 20% vested when the options were granted.
Exercise price of options | $ / shares			$ 0.18		$ 0.301
Option awards expences | $						$ 72,000	$ 0
Options granted					900,000
Issued options			500,000		300,000
Volatility rate	137%	132%	250%	137%
Discount rate			4.35%
Fair value of amortization | $			$ 114,531
Fair value of option granted | $					$ 484,205
April 1, 2016 [Member] | Option 1 [Member]
Common stock exercisable term						10 years
Exercise price of options | $ / shares						$ 0.30
Number of installments vest | integer						5
Issued options						40,000
April 1, 2016 [Member] | Option 2 [Member]
Common stock exercisable term						10 years
Exercise price of options | $ / shares						$ 0.30
Number of installments vest | integer						5
Options granted						30,000
April 1, 2018 [Member]
Issued options						40,000
April 1, 2018 [Member] | Option 1 [Member]
Exercise price of options | $ / shares						$ 0.25
Options granted						40,000
Fair value of option granted | $						$ 9,991
April 1, 2017 [Member] | Option 1 [Member]
Options granted						30,000

WARRANTS (Details)

WARRANTS (Details) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Number of warrants
Outstanding warrants, Beginning	3,700,000	0
Outstanding warrants, granted	1,000,000	3,700,000
Outstanding warrants, Exercised	(3,700,000)
Outstanding warrants, Ending	1,000,000	3,700,000
Weighted average exercise price
Weighted average exercise price, Beginning	$ 0.04	$ 0
Weighted average exercise price, Granted	0.60	0.15
Weighted average exercise price, Exercised	0	0
Weighted average exercise price, Expired	0	0
Weighted average exercise price, Ending	$ 0.60	$ 0.04
Weighted Average Remaining Contract Life
Weighted Average Remaining Contract life, Beginning	1 year 4 months 6 days
Weighted Average Remaining Contract life, Granted	1 year 9 months	2 years
Weighted Average Remaining Contract life, Ending	1 year 6 months	1 year 4 months 6 days
Intrinsic value
Intrinsic value, Beginning	$ 0	$ 0
Intrinsic value, granted	0	0
Intrinsic value, Exercised	0	0
Intrinsic value, Expired	0	0
Intrinsic value, Ending	$ 0	$ 0

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)			1 Months Ended		12 Months Ended
	Sep. 02, 2022	Apr. 07, 2022	Nov. 17, 2022	Aug. 31, 2022	Mar. 31, 2021	Mar. 31, 2023
Warrant Issued	250,000	500,000		750,000
Warrant outstanding						1,000,000
Exercise price of warrants	$ 0.345	$ 0.08		$ 0.41	$ 0.15
Warrants conversion price	$ 0.60	$ 0.12		$ 0.60	$ 0.15
Volatility rate	137%	132%	250%	137%
Discount rate	3.47%	1.78%		3.50%
Fair value of warrants	$ 50,273	$ 26,000		$ 188,760
Adjustments to additional paid-in capital, warrant issued	$ 2,484	$ 21,336		$ 9,902
Warrant converted into common stock						500,000
Warrant converted						500,000
Warrants descriptions					the Company granted 3,700,000 warrants to four entities as part of the issuance of 740,000 Series A convertible preferred shares.
Warrant [Member]
Warrants conversion price					$ 0.15
Fair value of warrants					$ 303,000
Deemed dividend from down round					555,000
Fair value of common stock					437,000
Proceeds from exercise of warrants					$ 349,605
Minimum [Member] | Warrant [Member]
Exercise price of warrants					$ 0.08
Volatility rate					312.50%
Discount rate					0.14%
Maximum [Member] | Warrant [Member]
Exercise price of warrants					$ 0.11
Volatility rate					314.49%
Discount rate					0.16%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Deferred tax assets:
Net operating loss	$ 1,757,783	$ 319,880
Less: Valuation allowance	(1,757,783)	(319,880)
Net deferred tax assets	$ 0	$ 0

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
INCOME TAXES
Federal net operating loss carry forwards	$ 13,544,358	$ 11,786,575
Federal tax rate	21%

CONVERTIBLE DEBT (Details Narra

CONVERTIBLE DEBT (Details Narrative) - USD ($)					1 Months Ended								12 Months Ended
	Sep. 02, 2022	Apr. 07, 2022	Aug. 10, 2021	Nov. 11, 2020	Mar. 31, 2023	Nov. 17, 2022	Aug. 31, 2022	Aug. 16, 2021	Apr. 22, 2021	Apr. 20, 2021	Feb. 16, 2021	Oct. 28, 2020	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Sep. 27, 2022	Sep. 20, 2022	Jul. 09, 2020	Jul. 07, 2020	May 07, 2020
Payment of Financing costs			$ 50,000					$ 35,000	$ 24,750	$ 41,400
Common stock issued, value													$ 823,975
Convertible notes					$ 23,975								23,975
Interest		$ 9,162			800,000								800,000
Notes payable,principal		275,000			$ 200,000								$ 200,000
Notes payable,premium		42,624
Notes paid,total		$ 326,786
Debt conversion, principle balance			200,000					$ 100,000	82,500	$ 138,000
Common stock shares par value					$ 0.001								$ 0.001	$ 0.001				$ 0.001		$ 0.20
Accrued interest			997,260		$ 700,000				$ 8,250			$ 6,805	$ 700,000	$ 50,000
Volatility rate	137%	132%				250%	137%
Common share issued, shares													9,539,197	1,858,862
Debtenture 1
Risk free interest rate													3.50%
Volatility rate													137%
Expected life													1 year
Debtenture 2
Risk free interest rate													4.03%
Volatility rate													140%
Expected life													1 year
Debtenture 3
Convertible debt																			$ 50,000
Risk free interest rate													3.98%
Volatility rate													141%
Expected life													1 year
August 31, 2022 [Member]
Conversion price, Description													Debenture may be converted at the lesser of $0.30 per share or eighty percent (80%) of the lowest VWAP of the Company’s common stock for ten consecutive trading days immediately prior to the conversion date and carried an original discount of 3% of the debenture face value
Warrant expiry date							Aug. 30, 2024
Exercise price of warrant													$ 0.60
Convertible debentures with unrelated party							$ 1,500,000
Debt paid,first installement							$ 500,000
Debt paid,second installement																	$ 500,000
Common stock issued for warrant purchase							750,000
Debt paid,third installement																$ 500,000
September 02, 2022 [Member]
Conversion price, Description													Debenture may be converted at the lesser of $0.30 per share or eighty percent (80%) of the lowest VWAP of the Company’s common stock for ten consecutive trading days immediately prior to the conversion date and carried an original discount of 3% of the debenture face value
Risk free interest rate													3.47%
Volatility rate													137%
Expected life													1 year
Warrant expiry date	Aug. 30, 2024
Exercise price of warrant													$ 0.60
Convertible debentures with unrelated party	$ 500,000
Debt paid,first installement	250,000
Debt paid,second installement	250,000
Common stock issued for warrant purchase	$ 250,000
8% Convertible Note [Member]
Convertible debt																			$ 50,000	$ 50,000
Series A Convertible Preferred Stock [Member]
Debt conversion, principle balance			$ 200,000	$ 7,500							$ 5,000	10,000
Accrued interest											5,000
Convertible debt		$ 275,000		$ 82,500							$ 100,000	$ 138,000
Conversion price, Description		Within 180 days of issuance, the note may be repaid at a premium of 115% of the face value of the note and 150% of the unconverted balance of the note after 180 days and prior to maturity. After 180 days the note may be converted into common stock of the Company at $0.075 per share or a 20% discount to the lowest VWAP (Volume- Weighted Average Pricing) price during the 10 days prior to conversion. The initial derivative was calculated using risk free interest of .05%, volatility of 132% and expected life of 0.50 years	Within 180 days of issuance the note may be repaid at an escalating premium up to 125% of the face value of the note. After 180 days the note may be converted into common stock of the Company at $0.06 per share or a 25% discount to the lowest trading price during the 10 days prior to conversion. The initial derivative was calculated using risk free interest of .05%, volatility of 132% and expected life of 0.50 years	After 180 days the note may be converted into common stock of the Company at a 35% discount to the lowest trading price during the 20 days prior to conversion							After 180 days the note may be converted into common stock of the Company at a 30% discount to the lowest trading price during the 15 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 213% and expected life of 1.00 years	After 180 days the note may be converted into common stock of the Company at $0.04 per share or a 30% discount to the VWAP during the 20 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 212% and expected life of .50 years			The stock is convertible into common stock at 10 cents per share or 50% of the lowest trading price, whichever is lower 5 days prior to conversion. The Company has the right to convert the shares nine months after the issuance. The warrants are convertible at $0.15 per share within two years of issuance
Risk free interest rate		8%	10%	10%							10%
Debt maturity date		Mar. 29, 2023	Feb. 10, 2022	Oct. 28, 2021							Feb. 16, 2022	Oct. 28, 2021
Interest rate					80%							10%

LICENSE AGREEMENT (Details Narr

LICENSE AGREEMENT (Details Narrative) - BioRay Pharmaceutical Co LTD [Member]	12 Months Ended
	Mar. 31, 2023 USD ($)
Agreement description	Under the terms of the agreement the Company receives $250,000 upon signing of the agreement plus $750,000 with the start of the phase 1 clinical trials , which started in March 2021. In addition, the Company received $750,000 upon the initial patient enrolled at the dosage level of 8.0 mg/kg. Further payment of $2,500,000 will be received when the FDA approves the phase 2 clinical trials and $750,000 when the phase 2 clinical trials begin.
Received payment net	$ 1,750,000
Issuance of license agreement	$ 5,000,000
Royalty rate	9%
Net sales	20 years

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)		1 Months Ended		12 Months Ended
	Mar. 09, 2020	Sep. 30, 2020	Jun. 30, 2016	Mar. 31, 2023
Contingent sales fee description			A contingent sales fee upon product sales of 1% of sales or $150,000 whichever is greater.
Merger, description	Under the program, if an acquisition, merger or change in control is affected, 10% of the value of the transaction will be allocated to pay the expenses of the transaction including but not limited to legal, accounting, transfer fees and other miscellaneous expense. The balance of the fund after expenses will be allocation 20% to directors and 80% to officers and employees of the Company as allocated by the Chief Executive Officer and approved by the Board of Directors.	Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company
Annual Maintenance				$ 19,300
First Phase I clinical trial [Member]
Future payments			$ 100,000
Annual maintenance fee			50,000
First Phase III clinical trial [Member]
Future payments			225,000
First BLA [Member]
Future payments			$ 225,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	May 30, 2023	May 24, 2023	May 17, 2023	May 01, 2023	Mar. 31, 2023	Mar. 31, 2022
Common stock					$ 131,764	$ 111,313
Subsequent Event [Member]
Common share issued	100,000	4,367,842	1,331,919	3,837,419
Conversion of convertible notes		$ 150,000	$ 45,000	$ 150,000
Common stock	$ 5,600	165,978	50,240	151,578
Accrued interest		$ 15,978	$ 5,240	$ 1,578